Kyle R Noll1, Mariana E Bradshaw1, Jeffrey S Weinberg2, Jeffrey S Wefel1. 1. Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: Cancer and treatment-related neurocognitive dysfunction has the potential to significantly disrupt the lives of survivors. While neurocognitive functioning is known to predict aspects of patient-reported quality of life in individuals with glioma, little is known regarding the association between neurocognitive functioning and clinician-rated functional independence. METHODS: Newly diagnosed patients with glioma in the left (n = 73; 49% glioblastoma) or right (n = 30; 57% glioblastoma) temporal lobe completed comprehensive neuropsychological testing. Clinicians rated patient functional independence using the Functional Independence Measure (FIM) and Karnofsky Performance Status (KPS) scale. Correlational and regression analyses were conducted to determine relationships between neurocognitive functioning and functional independence. RESULTS: Tests of verbal learning, executive function, and language comprehension were moderately to strongly associated with clinician-rated functional independence, particularly for items pertaining to need for assistance with memory, problem-solving, and language functions. Stepwise linear regression showed that tests of verbal learning, executive functioning, and language comprehension predicted FIM ratings, together accounting for 40% of variance (P < .001). A test of executive functioning also predicted KPS scores and accounted for 19% of variance (P < .001). CONCLUSIONS: In patients with newly diagnosed temporal lobe glioma, neurocognitive functioning is associated with functional independence. Verbal learning, executive functioning, and language comprehension demonstrated the strongest associations across both measures of functional independence. These findings provide support for the ecological validity of neuropsychological assessment by demonstrating the real-world clinical significance of objectively assessed neurocognitive functioning in glioma patients.
BACKGROUND: Cancer and treatment-related neurocognitive dysfunction has the potential to significantly disrupt the lives of survivors. While neurocognitive functioning is known to predict aspects of patient-reported quality of life in individuals with glioma, little is known regarding the association between neurocognitive functioning and clinician-rated functional independence. METHODS: Newly diagnosed patients with glioma in the left (n = 73; 49% glioblastoma) or right (n = 30; 57% glioblastoma) temporal lobe completed comprehensive neuropsychological testing. Clinicians rated patient functional independence using the Functional Independence Measure (FIM) and Karnofsky Performance Status (KPS) scale. Correlational and regression analyses were conducted to determine relationships between neurocognitive functioning and functional independence. RESULTS: Tests of verbal learning, executive function, and language comprehension were moderately to strongly associated with clinician-rated functional independence, particularly for items pertaining to need for assistance with memory, problem-solving, and language functions. Stepwise linear regression showed that tests of verbal learning, executive functioning, and language comprehension predicted FIM ratings, together accounting for 40% of variance (P < .001). A test of executive functioning also predicted KPS scores and accounted for 19% of variance (P < .001). CONCLUSIONS: In patients with newly diagnosed temporal lobe glioma, neurocognitive functioning is associated with functional independence. Verbal learning, executive functioning, and language comprehension demonstrated the strongest associations across both measures of functional independence. These findings provide support for the ecological validity of neuropsychological assessment by demonstrating the real-world clinical significance of objectively assessed neurocognitive functioning in glioma patients.
Authors: Jennifer L Helfer; Patrick Y Wen; Jaishri Blakeley; Mark R Gilbert; Terri S Armstrong Journal: Neuro Oncol Date: 2016-03 Impact factor: 12.300
Authors: Katrin Jekel; Marinella Damian; Carina Wattmo; Lucrezia Hausner; Roger Bullock; Peter J Connelly; Bruno Dubois; Maria Eriksdotter; Michael Ewers; Elmar Graessel; Milica G Kramberger; Emma Law; Patrizia Mecocci; José L Molinuevo; Louise Nygård; Marcel Gm Olde-Rikkert; Jean-Marc Orgogozo; Florence Pasquier; Karine Peres; Eric Salmon; Sietske Am Sikkes; Tomasz Sobow; René Spiegel; Magda Tsolaki; Bengt Winblad; Lutz Frölich Journal: Alzheimers Res Ther Date: 2015-03-18 Impact factor: 6.982
Authors: Tobin Ehrlich; Anny Reyes; Brianna M Paul; Vedang Uttarwar; Stephen Hartman; Kushagra Mathur; Yu-Hsuan A Chang; Manu Hegde; Jerry J Shih; Carrie R McDonald Journal: Epilepsy Res Date: 2018-11-13 Impact factor: 3.045
Authors: Sophie J M Rijnen; Ikram Meskal; Marjan Bakker; Wouter De Baene; Geert-Jan M Rutten; Karin Gehring; Margriet M Sitskoorn Journal: Neuro Oncol Date: 2019-07-11 Impact factor: 12.300
Authors: Kathleen Van Dyk; Lucy Wall; Brandon F Heimberg; Justin Choi; Catalina Raymond; Chencai Wang; Albert Lai; Timothy F Cloughesy; Benjamin M Ellingson; Phioanh Nghiemphu Journal: CNS Oncol Date: 2022-05-18
Authors: Sophie J M Rijnen; Elke Butterbrod; Geert-Jan M Rutten; Margriet M Sitskoorn; Karin Gehring Journal: Neurosurgery Date: 2020-11-16 Impact factor: 4.654